Spyryx Biosciences: About Us

Spyryx Biosciences is pioneering the use of novel peptides to treat severe pulmonary diseases where airway dehydration and reduced mucus clearance are initiating factors in disease progression. Our compounds have a novel mechanism of action that increases airway fluid levels to hydrate mucus and promote mucociliary clearance, with the therapeutic goal of enhancing lung performance. Spyryx’s lead program, SPX-101, is in Phase 2 testing for cystic fibrosis.